Document Detail

XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
MedLine Citation:
PMID:  17187467     Owner:  NLM     Status:  MEDLINE    
Drug-eluting stents (DES) have been shown to be safe and significantly reduce clinical events and angiographic restenosis in the percutaneous treatment of coronary artery disease. Currently, three DES have been approved in Europe and Northern America: the sirolimus-eluting stent (SES), the paclitaxel-eluting stent (PES) and the zotarolimus-eluting stent (ZES). Everolimus, an analog of sirolimus, is an immunosuppressive and antiproliferative agent. In three studies, the SPIRIT I, FUTURE I and II, the everolimus-eluting stent has proven to be safe, well-tolerated and has shown very favorable clinical and angiographic results. Compared with earlier-generation DES, the XIENCE V everolimus-eluting coronary stent system (Advanced Cardiovascular Systems Inc., an Abbott Vascular Company, CA, USA) may provide enhanced deliverability, radiopacity with thinner strut filaments and, owing to a durable polymer, sustained drug elution and vascular compatibility.
Marcel A M Beijk; Jan J Piek
Related Documents :
17408117 - In vivo cardiovascular assays for drug discovery: evolution of the drug-eluting stent.
17992397 - Does the use of paclitaxel or rapamycin-eluting stent decrease further need for coronar...
15353867 - Procedural results and distal embolization after saphenous vein graft stenting and angi...
15350167 - Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis.
16251397 - Arterial blood supply to the posterior aspect of segment iv of the liver from the cauda...
25159557 - Foetal therapy: what works? closed interatrial septum.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of medical devices     Volume:  4     ISSN:  1743-4440     ISO Abbreviation:  -     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-01-12     Completed Date:  2007-03-22     Revised Date:  2008-06-05    
Medline Journal Info:
Nlm Unique ID:  101230445     Medline TA:  Expert Rev Med Devices     Country:  England    
Other Details:
Languages:  eng     Pagination:  11-21     Citation Subset:  IM    
Academic Medical Center, University of Amsterdam, Department of Cardiology, Meibergdreef 9, PO Box 22660, 1105 AZ Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Coronary Artery Disease / drug therapy*
Coronary Restenosis / prevention & control*
Drug Delivery Systems*
Immunosuppressive Agents / administration & dosage*
Paclitaxel / administration & dosage
Sirolimus / administration & dosage,  analogs & derivatives*
Technology Assessment, Biomedical
Reg. No./Substance:
0/Immunosuppressive Agents; 0/zotarolimus; 159351-69-6/everolimus; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cell transplantation for treatment of left-ventricular dysfunction due to ischemic heart failure: fr...
Next Document:  P-Stim auricular electroacupuncture stimulation device for pain relief.